About Leadsynbio
Leadsynbio is a company based in Suzhou (China) founded in 2015 by Xie Xinkai. Leadsynbio has raised $67.07 million across 2 funding rounds from investors including Lilly Asia Ventures and Sherpa Healthcare Partners. Leadsynbio operates in a competitive market with competitors including Viyash, Inventys, Blue Jet Healthcare, Ami organics and Aparna Pharmaceuticals, among others.
- Headquarter Suzhou, China
- Founders Xie Xinkai
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website leadsynbio.com
- Total Equity Funding$67.07M (USD)
in 2 rounds
- Latest Funding Round$67.07M (USD), Series E
Sep 2026
- InvestorsLilly Asia Ventures
& 1 more
Funding Insights of Leadsynbio
Leadsynbio has successfully raised a total of $67.07M across 2 strategic funding rounds. The most recent funding activity was a Series E round of $67.07 million completed in September 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $67.07M
- Total Rounds 2
- Last Round Series E — $67.07M
- Investors Count 2
All 2 funding rounds of Leadsynbio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2026 | $67.07M | Series E | – | – | – |
| Aug 2023 | – | Series D | – | Lilly Asia Ventures, Sherpa Healthcare Partners | – |
2 investors in total: 2 institutional.
Investors in Leadsynbio
Leadsynbio has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly Asia Ventures and Sherpa Healthcare Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | sherpahp.com | - | |
- | – | lillyasiaventures.com | - |
Investor details for Leadsynbio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Leadsynbio
1 people are tracked at Leadsynbio (1 in leadership).
| Name | Role | Group |
|---|---|---|
Xie Xinkai | Founder & CEO | Leadership |
Complete people profiles for Leadsynbio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Leadsynbio
3 dated milestones of Leadsynbio across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Leadsynbio is founded.
- Funding First funding round.
- Funding Latest funding round, Series E, of $67.1M.
Competitors of Leadsynbio
Leadsynbio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Viyash, Inventys, Blue Jet Healthcare, Ami organics and Aparna Pharmaceuticals, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| viyash.com | 2019 | Hyderabad, India | $120.02M | 277 | APIs and intermediates are manufactured by Viyash as a CDMO. | |
| inventys.in | 2005 | Mumbai, India | $64.34M | 219 | Actives, advanced intermediates, and specialty chemicals are custom manufactured. | |
| bluejethealthcare.com | 1969 | Mumbai, India | – | 476 | CDMO focused on manufacturing, supplier, and development of intermediates & APIs | |
| amiorganics.com | 2007 | Surat, India | – | 4 | Advanced API intermediates are manufactured for pharmaceutical use. | |
| aparnapharma.com | 2008 | Hyderabad, India | $674,328 | 328 | API intermediates are manufactured by Aparna Pharmaceuticals as a CDMO. | |
| dudechem.com | 2019 | Berlin, Germany | $6.98M | – | CDMO focused on manufacturing of APIs and intermediates | |
| hindyslab.com | 2007 | Hyderabad, India | – | 285 | Manufactures and exports pharmaceutical intermediates for global markets. | |
| hsbiopharm.com | 2004 | Hangzhou, China | – | – | APIs, intermediates, and finished dosage forms are manufactured. | |
| enantilabs.com | 2007 | Hyderabad, India | – | 178 | Enanti Labs produces pharmaceutical intermediates and APIs in India with quality focus. |
Detailed competitors of Leadsynbio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Leadsynbio
10 companies that operate in the same segment as Leadsynbio (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 255.15 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Leadsynbio
Leadsynbio was founded in 2015 and raised its 1st funding round 8 years after it was founded.
Leadsynbio is headquartered in Suzhou, China. It is registered at Suzhou, Jiangsu, China.
Xie Xinkai is the current CEO of Leadsynbio. They have also founded this company.
Leadsynbio is a funded company, having raised a total of $67.07M across 2 funding rounds to date.
Leadsynbio was founded in 2015 and is based in Suzhou, China. Operations are centered on contract development and manufacturing organization (CDMO) services within the synthetic biology sector. Intermediates for biotech applications are produced through specialized manufacturing processes. Leadership is provided by founder and CEO Xie Xinkai. The companys domain, leadsynbio.com, supports its focus on these core activities.
Leadsynbio's top competitors include Inventys, Viyash and Blue Jet Healthcare.
Leadsynbio has 2 investors. Key investors include Lilly Asia Ventures, and Sherpa Healthcare Partners.